Publication|Articles|July 7, 2025
Supplements and Featured Publications
- Targeting Tear Evaporation: How Perfluorohexyloctane Ophthalmic Solution Redefines the Management of Evaporative Dry Eye Disease
Targeting Tear Evaporation: How Perfluorohexyloctane Ophthalmic Solution Redefines the Management of Evaporative Dry Eye Disease
Listen
0:00 / 0:00
Advertisement
This clinical brief is supported by Bausch + Lomb.
This AJMC® Clinical Brief provides a primer on dry eye disease (DED) diagnosis, pathophysiology, and treatment, highlights a DED treatment, and discusses real-world data about patient treatment satisfaction.
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
As Cencora Closes With OneOncology, Patton Says Terms Show “Trust”
2
TrumpRx Launch Brings Savings—and Uncertainty
3
Exploring Identity, Appearance Experiences Among Patients With Alopecia
4
5 Things to Know About the Oral GLP-1 Era
5
